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Streszczenie
Wstęp Celem pracy była ocena związku pomiędzy stężeniem
homocysteiny a występowaniem nadciśnienia tętniczego.
Materiał i metody W badaniu uczestniczyło 88 pacjentów
z nadciśnieniem tętniczym (62 mężczyzn i 26 kobiet,
w wieku 18–72 lat) i 120 zdrowych ochotników (87 męż-
czyzn i 33 kobiety, w wieku 32–81 lat). Stężenie homocyste-
iny w osoczu na oznaczono metodą FPI (Fluorescence Pola-
rization Immunoassay), stężenie kwasu foliowego i witami-
ny B12 oznaczono metodą chemiluminescencji.
Wyniki Stężenie homocysteiny było większe w grupie pacjen-
tów niż w grupie kontrolnej (12,07 ± 5,1 vs. 10,72 ±
± 2,13 mmol/l, p < 0,001, skorygowane względem wieku).
Podwyższone stężenie homocysteiny — definiowane jako stę-
żenie powyżej 90 percentyla rozkładu w grupie kontrolnej
(≥ 13,52 mmol/l) — zaobserwowano u 24% pacjentów
i u 10% osób z grupy kontrolnej. Iloraz szans (OR, odds ratio)
wystąpienia nadciśnienia tętniczego u osób z podwyższonym
stężeniem homocysteiny wyniósł 2,8 (95-procentowy przedział
ufności 1,3–6,1, p < 0,01). W analizie wieloczynnikowej, po
uwzględnieniu innych czynników ryzyka (wiek, płeć, wskaź-
nik masy ciała, palenie tytoniu, występowanie chorób układu
krążenia w rodzinie, hiperlipidemia), podwyższone stężenie
homocysteiny pozostało niezależnym czynnikiem ryzyka nad-
ciśnienia tętniczego (OR 6,6, 95-procentowy przedział ufności
2,3–19,1, p < 0,001). Iloraz szans wystąpienia nadciśnienia
tętniczego przy wzroście stężenia homocysteiny o 5 mmol/l
wyniósł 1,7 (95-procentowy przedział ufności 1,1–2,6,
p < 0,001), a w analizie wieloczynnikowej 3,8 (95-procentowy
przedział ufności 1,7–8,2, p < 0,001).
Wnioski Podwyższone stężenie homocysteiny jest ważnym
czynnikiem ryzyka nadciśnienia tętniczego. Wzrost stęże-
nia homocysteiny o 5 mmol/l może wiązać się z co najmniej
2-krotnym wzrostem ryzyka nadciśnienia tętniczego.
słowa kluczowe: homocysteina, nadciśnienie tętnicze,
kwas foliowy, witamina B12
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Introduction
The importance of hyperhomocysteinemia in the
pathogenesis of atherosclerosis was recognised in 1969,
when McCully [1] reported evidence of atherosclerosis
in children with homocysteinuria and elevated plasma
homocysteine concentrations. Since then, prospective
and retrospective studies, like the Physicians’ Health
nadciśnienie tętnicze rok 2002, tom 6, nr 2
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Study [2] or the European Concerted Action Project [3],
confirmed the association between hyperhomocyste-
inemia and cardiovascular disease. In many clinical tri-
als subjects with elevated homocysteine levels had in-
creased risk of coronary artery disease [4, 5], stroke [6]
and intima-media thickness [7] or peripheral vascular
disease (PVD) [8, 9]. The role of homocysteine in
atherogenesis remains unclear. Hyperhomocysteinemia
may be associated with endothelial-cell injury and dys-
function [10–12], followed by platelet activation and
thrombus formation, lipid peroxydation, LDL-oxyda-
tion [13–14] and proliferation of vascular smooth-mus-
cle cells [15]. Homocysteine makes a prothrombotic en-
vironment in the vessel, by activating factors V and XII
[16], and by depressing protein C [17]. Another hypoth-
esis is that homocysteine may be a risk factor for hyper-
tension and accelerate the atherosclerotic process
through increasing blood pressure. The animal model
shows that hyperhomocysteinemia may be a reason for
hypertension [18]. The minipigs fed with a methionine-
based diet developed hyperhomocysteinemia after
4 months. They also presented with systolic-diastolic
hypertension and extended reactive hyperaemia as well
as mega-artery syndrome in hyperpulsatile arteries due
to expanded volumetric compliance, curtailed stiffness,
strengthened vascular tension and prevalence of the vis-
cous wall component. In their arterial tree hypertrophic
endothelial cells covered a thickened subendothelial
space. Similarly, in fructose-fed rats, elevated blood pres-
sure was observed with an elevation of homocysteine
level [19]. Also in human study with hypertensive pa-
tients, homocysteine correlated with aortic stiffness,
measured as the carotid-femoral pulse wave velocity
[20]. So the aim of this study was to assess the potential
association between the prevalence of essential hyper-
tension and total homocysteine concentrations.
Material and methods
Patients and controls
88 consecutive patients (62 men and 26 women, aged
18 to 72 years) with essential hypertension and 120
healthy controls (87 men and 33 women, aged 32–81
years) were studied. Informed consent was obtained
from all patients and controls. Questionnaires provid-
ing information about all risk factors, such as smoking,
hyperlipidemia, diabetes mellitus and family history of
premature cardiovascular disease, were completed.
Definitions
The Body Mass Index was calculated using the
standard formula. Hypertension was defined as blood
pressure ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg
(diastolic) or if patient was taking any antihyperten-
sive medications because of previously diagnosed
hypertension.
Hyperlipidemia was defined if the total cholester-
ol level was > 200 mg% or LDL-cholesterol level
was > 130 mg% or if patient was taking a lipid-
-lowering drug.
Smokers were defined as those currently smoking
any tobacco or those who had stopped smoking less
than 6 months before study.
Family history of cardiovascular disease (CVD)
was considered present if the coronary artery disease
or hypertension was documented in first-degree re-
lative before 65 years.
Diabetes mellitus was diagnosed if patient was tak-
ing oral hypoglycaemic agents or insulin, or if the fast-
ing serum glucose level was greater than 140 mg%.
Elevated homocysteine level was defined as a le-
vel greater than 90th percentile for control subjects
(level ≥ 13,52 mmol/L). Plasma folate and vitamin
B12 deficiencies were defined as the levels below 10th
percentile of the control distribution (£ 7,4 nmol/L
and £ 143,48 pmol/L, respectively).
Biochemical Measurements
The blood was drawn in the fasting state. Plasma
total homocysteine level, including protein-bound
and free homocysteine, was measured using Fluo-
rescence Polarisation Immunoassay (FPIA) on the
IMx Analyser, made by Axis Biochemicals.
Plasma folate and plasma vitamin B12 were as-
sayed with chemiluminescency and IMMULITE
Automated Analyser made by Diagnostic Products
Corporation.
Concentrations of total fasting cholesterol, high-
-density lipoprotein, triglycerides and glucose were
measured using standard laboratory techniques. Low
density-lipoprotein cholesterol was calculated by the
formula of Friedewald for patients with serum tri-
glyceride concentrations below 354 mg%.
Statistical Analysis
All continuous variables are reported as mean plus
or minus one standard deviation. Differences in car-
diovascular risk factors between patients and con-
trols were tested with Student’s T-test for continu-
ous variables and c2–test for comparison of frequen-
cies. A two-sided 5% level of significance was consi-
dered significant.
Logistic regression was used to examine the risk
for hypertension conferred by elevated homocysteine
level and 5 mmol/L homocysteine increment. Pear-
son’s correlation of the vitamins and plasma homo-
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cysteine levels was calculated. The comparison of
homocysteine and vitamins levels, according to the
levels of diastolic blood pressure, was made using
analysis of variance (Duncan’s multiple range test).
The statistical analysis was performed using SAS
System 6.12.
Results
Characteristics of the studied group
There were no differences between patients and con-
trols as for age, gender and lipid concentrations. Patients
had higher body mass index and more often family his-
tory of CVD. In 10% of patients diabetes mellitus was
diagnosed, 12% of patients were smokers. The charac-
teristics of the studied group are presented in Table I.
Total plasma homocysteine concentrations
Total plasma homocysteine concentrations were
higher in patients than in controls (12,07 ± 5,1 vs.
10,72 ± 2,13 mmol/L, p< 0,05). Male patients had
also significantly higher homocysteine levels than
male controls (12,47 ± 5,24 vs. 10,81 ± 2,07 mmol/L,
p < 0,05). This difference was not observed between
female patients and controls (11,12 ± 4,54 vs. 10,47 ±
± 2,31 mmol/L, p = ns). The subjects with obesity
had higher homocysteine than subjects with normal
weight (12,86 ± 4,46 vs. 11,18 ± 3,58 mmol/L,
p < 0,05). The mean levels of homocysteine in partic-
ular subgroups of patients are presented in Table II.
Homocysteine slightly correlated with BMI in all
subjects (r = 0,15, p < 0,05), and did not correlate with
age and vitamin B12 level. In all subjects an inverse
correlation between homocysteine and folic acid was
noted (r = –0,22, p < 0,01). This correlation was much
stronger in hypertensive patients (r = –0,34, p < 0,01)
than in the controls (r = –0,27, p < 0,05).
Elevated homocysteine level was seen in 24% of pa-
tients, compared with 10% of the controls (p < 0,01).
The odds ratio (OR) for hypertension in subjects
with elevated homocysteine level was 2,8 (95% CI
1,3–6,1, p < 0,01). In male subjects this OR was
even higher — 3,0 (95% CI 1,2–7,4, p < 0,05).
After adjustment for other risk factors (age, BMI,
smoking, family history of CVD, hyperlipidemia), ele-
vated homocysteine level remained an independent
risk factor for hypertension — the OR in all the stu-
died group was 6,6 (95% CI 2,3–19,1, p < 0,001) and
in the male subgroup 8,4 (95% CI 2,4–28,9, p < 0,001).
When homocysteine was considered as a continuous
variable, the odds ratio for hypertension of 5 mmol/L
increment in plasma homocysteine level was 1,7
(95% CI 1,1–2,6, p < 0,001) in all subjects and 1,9
(95% CI 1,1–3,2, p < 0,05) in males. In multivariate
analysis the OR for hypertension was 3,8 (95% CI
1,7–8,2, p < 0,001) in all the studied group and
7,4 (95% CI 2,6–21,3, p < 0,001) in the male subgroup.
Vitamin concentrations in patient population
There were no significant differences in vitamin
levels between patients and controls. Mean plasma
folate level in patients was 17,16 ± 7,87 nmol/L com-
Table I. Demographic characteristics and risk factor profiles of patients and controls
Tabela I. Porównanie czynników ryzyka w grupie badanej i kontrolnej
Variable Cases Controls P
No. 88 120
Mean age (y) 45.93 ± 11.92 47.26 ± 8.69 NS
Male (%) 70.5 72.5 NS
BMI [kg/m2] 27.5 ± 3,8 25.8 ± 3.7 < 0.01
Obesity (%) 26 12.5 < 0.05
Current smoker (%) 12 41 < 0.05
Hyperlipidemia (%) 67 41 0.001
Family history of CVD (%) 30 17.5 0.05
Cholesterol (mean ± SD) (mg%) 221.27 ± 44.32 211.37 ± 43.35 NS
LDL-cholesterol (mean ± SD) (mg%) 137.6 ± 33.67 127.84 ± 40.16 NS
HDL-cholesterol (mean ± SD) (mg%) 51.33 ± 11.86 54.23 ± 12.64 NS
Triglycerides (mean ± SD) (mg%) 145.44 ± 74.33 144.92 ± 105.66 NS
BMI, body mass index, indeks masy ciała; LDL, low-density lipoprotein, lipoproteina o niskiej gęstości; HDL, high-density lipoprotein, lipoproteina
o wysokiej gęstości; CVD, cardiovascular disease, choroba układu sercowo-naczyniowego
nadciśnienie tętnicze rok 2002, tom 6, nr 2
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pared with 15,86 ± 12,39 nmol/L in control group.
Folate deficiency was found in 5,4% of patients and
10,6% of controls. All males had non-significantly low-
er folate level than females (15,33 ± 9,87 vs. 20,05 ±
± 13,22 nmol/L). This difference was observed in
smoking subjects, who had a much lower level of
folate than non-smokers (12,54 ± 5,48 compared with
17,61 ± 12,22 nmol/L). Patients with elevated homo-
cysteine level had much lower folate concentrations
than patients with normal homocysteine concentra-
tion (12,42 ± 6,12 vs. 17,27 ± 11,47, p < 0,01).
Plasma folate level did not correlate with age or
vitamin B12. The correlation between folate and BMI
was significant only in the control group (r = –0,29,
p < 0,01), but in all studied subjects this correlation
was weak (r = –0,15, p = 0,07).
Vitamin B12 in patients and controls were 259,78 ±
± 127,13 and 245,7 ± 109,8 pmol/L, respectively. Vita-
min B12 deficiency was seen in 7,3% of patients and
10,3% of controls. Plasma vitamin B12 concentrations
did not correlate with age or BMI, either in hypertensive
or healthy subjects. The concentrations of vitamins in
particular subgroups of subjects are presented in Table II.
Analysis of correlation of homocysteine
and vitamins with blood and pulse pressure
Homocysteine tended to be correlated with
systolic (SBP) and diastolic blood pressure (DBP),
although most patients had been pharmacologically
treated. Although the correlation with SBP (r = 0,21,
p = 0,07) and with DBP (r = 0,2, p = 0,09) was not
significant, homocysteine concentration was related
to DBP level. Patients with higher DBP had much
higher homocysteine levels and much lower folic acid
concentrations, as presented in Table III. Folate and
vitamin B12 strongly correlated with systolic and dia-
stolic blood pressure, as is shown in Table IV.
Homocysteine and folate were not associated with
pulse pressure, in contrast to vitamin B12, which cor-
related significantly (r = –0,29, p < 0,05).
Table III. Mean homocysteine and vitamin levels according to the diastolic blood pressure
Tabela III. Stężenia homocysteiny i witamin w zależności od rozkurczowego ciśnienia
tętniczego w grupie pacjentów
Diastolic blood pressure Mean tHcy Mean folic acid Mean B12
[mm Hg] (mmol/L) (nmol/L) (pmol/L)
£ 90 11.93 19.81 292.62
91–105 12.29 15.58 238.69
> 105 16.77 11.63 215.19
P 0.06 < 0.05 NS
Table II. Plasma total homocysteine, folate and vitamin B12 levels in particular subgroups
of subjects
Tabela II. Stężenia homocysteiny, kwasu foliowego i witaminy B12 w poszczególnych
podgrupach badanych osób
Mean SD Mean folic SD Mean B12 SD
tHcy acid (pmol/L)
(mmol/L) (nmol/L)
Men 11.50 3.80 15.33 9.87 251.12 118.36
Women 10.76 3.45 20.05 13.22 251.26 111.83
Obese patients 12.86* 4.46 15.64 8.48 248.72 133.58
Non-obese patients 11.18 3.58 16.38 11.41 253.77 115.23
Smokers 11.54 3.77 12.54** 5.48 245.06 134.09
Non-smokers 11.47 3.75 17.61 12.22 254.63 112.48
With hyperlipidemia 11.79 3.91 15.44 6.83 240.11 106.89
Without hyperlipidemia 11.05 2.83 16.33 12.63 267.26 131.23
With family history of CVD 11.58 2.79 18.76 14.13 248.91 141.14
Without family history of CVD 11.25 3.37 15.64 10.47 258.31 113.84
*p < 0.05, **p < 0.01, in other p = NS. Thcy, total homocysteine, całkowite stężenie homocysteiny; CVD, cardiovascular disease, choroba układu
sercowo-naczyniowego
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Discussion
The definition of an elevated homocysteine level
is still being discussed. In most studies it is deter-
mined as the 80th, 90th or 95th percentile of the homo-
cysteine distribution in control population. In this
study, a level over the 90th percentile was chosen ar-
bitrarily. Then we observed that subjects with an ele-
vated homocysteine level had a more than twofold
increase of risk for hypertension, compared with
those with values in the bottom 90% of the controls
(OR 2,88, 95% CI 1,1–7,8).The OR in men was even
higher — 3,7. An elevated homocysteine level re-
mained an independent risk factor after adjustment
for other risk factors. These odds ratios were not sig-
nificant in women, most probably because of the
small number of females included in the trial.
Homocysteine tended to be correlated with systolic
and diastolic blood pressure, despite the majority of
patients having taken antihypertensive drugs.
Nevertheless, the results of studies assessing the
relationship between blood pressure or prevalence of
hypertension and hyperhomocysteinemia are equi-
vocal both in cohort studies with healthy subjects
and in case-control studies.
A significant positive association between homo-
cysteine and blood pressure was observed in the Hor-
daland Homocysteine Study [21]. In this study, in-
cluding over 16 000 healthy subjects, homocysteine
correlated with diastolic blood pressure (DBP), espe-
cially in middle-aged men. Male subjects with DBP
over 100 mm Hg had almost 1 mmol/L higher homo-
cysteine level than those with DBP below 70 mm Hg.
The relationship was graded and significant after ad-
justment for other risk factors like age, sex, smoking
status, physical activity and lipids levels. However, ho-
mocysteine was determined in non-fasting state.
Also Bates et al. [22], who determined homo-
cysteine in almost one thousand UK people aged
over 65 years, found the association between homo-
cysteine and DBP.
A positive correlation between homocysteine and
blood pressure was noted in non-insulin-dependent
diabetes mellitus (NIDDM) patients, both normo-
and hypertensive. Normotensive patients with eleva-
ted homocysteine levels had significantly higher diasto-
lic blood pressure and mean arterial pressure. In that
study, Fiorina et al. [23] extrapolate the results and
conclude that a twofold increase in homocysteine level
(from 6 to 12 mmol/L) is associated with a 4,5 mm Hg
rise in DBP values and this means three more strokes
per ten patients. When homocysteine increased three-
fold, they observed an increase of 8 mm Hg in DBP
values. In the study performed by Stabler et al. [24],
including 452 subjects with NIDDM and mean dia-
stolic blood pressure 80 mm Hg or higher, total ho-
mocysteine level correlated with systolic blood pres-
sure and duration of hypertension.
Verhoef et al. [25] investigated almost six hundred
subjects participating in the Physicians’ Health Study:
109 subjects who developed ischaemic stroke and
427 controls. Although she did not show the relation-
ship between homocysteine and stroke, she found that
hypertensive controls had a much higher homo-
cysteine level than normotensive ones (11,8 compared
with 10,3 mmol/L). This difference was not observed
in the patients’ group.
The results of case-control studies including hy-
pertensive patients are very interesting. In the study
performed by Sutton-Tyrrell et al. [26], including
179 patients aged over 60 years with isolated systolic
hypertension and 171 healthy subjects, homocysteine
remained an independent risk factor for systolic hy-
pertension. Each 10 mmol/L increment in homo-
cysteine level increased twofold the risk of systolic
hypertension. Moreover, when all subjects were clas-
sified according to JNC V criteria, homocysteine val-
ues increased with each stage.
Similarly, Chambers et al. [27] investigated ho-
mocysteine in 299 hypertensive males and 715 age-
matched normotensive controls. Hypertensive sub-
jects had a higher homocysteine level both in the
fasting state and after methionine load. The rela-
tionship between elevated homocysteine level and
hypertension was graded and independent of body-
mass index, waist-hip ratio, glucose, triglicerydes and
HDL-cholesterol.
Also Sheu and Mendis observed an association
between homocysteine level and prevalence of hy-
pertension in their Chinese and Sri Lankan studies,
including similar groups of subjects. Sheu [28] in-
vestigated 90 Chinese hypertensive patients and they
had a higher homocysteine level than 86 age- and
Table IV. Correlations (r-Pearson) between homocysteine,
vitamins and blood pressure. SBP, systolic blood pressure;
DBP, diastolic blood pressure
Tabela IV. Korelacje pomiędzy stężeniem homocysteiny,
witamin a ciśnieniem tętniczym. SBP, skurczowe ciśnienie
tętnicze; DBP, rozkurczowe ciśnienie tętnicze
SBP DBP
Homocysteine 0.21 0.2
Folic acid –0.31* –0.31*
Vitamin B12 –0.48** –0.33*
*p < 0.05, **p < 0.001
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sex-matched controls (8,1 vs. 6,8 mmol/L, p < 0,05).
In the Sri Lanka study [29], subjects with homo-
cysteine concentration above 18 mmol/L had an al-
most threefold increase of risk for hypertension.
Malinow et al. found [30] that hypertension was
more common among patients with peripheral vas-
cular disease (PVD) and high plasma homocysteine
levels than in subjects with PVD but with normal
homocysteine levels. In contrast, this author with
other colleagues [31] showed that high levels of ho-
mocysteine were indeed related to cerebral infarcts
but were unrelated to the presence of elevated blood
pressure.
The relationship between homocysteine and hy-
pertension was observed also in studies with black
Americans. In one study [32], a positive correlation
between homocysteine and systolic and diastolic blood
pressure was found in female subjects (r = 0,54,
r = 0,69, respectively).
In another case-control study, Sharabi and col-
leagues [33] studied the potential relationship be-
tween homocysteine level and history of cardiac or
cerebral events in 100 patients with hypertension.
Although homocysteine did not appear to be the pre-
dictor of atherothrombotic events, its mean concen-
tration in all hypertensive patients was much higher
than determined in the same laboratory in 250
healthy subjects.
Alternatively, it is possible that there is no associa-
tion between hypertension and plasma homocysteine
and they are unrelated risk factors with no synergic
or additive effects.
Several studies did not confirm the hypothesis that
homocysteine promotes atherosclerosis through ele-
vated blood pressure. No correlation between homo-
cysteine and blood pressure was found in almost six
hundred healthy French Canadians and 150 subjects
with coronary artery disease [34].
Whincup et al. [35] determined homocysteine con-
centrations in almost four hundred middle-aged men
after myocardial infarction and 454 age-matched con-
trols but the association between systolic or diastolic
blood pressure and homocysteine was not observed.
Similarly, Brattstrom et al. [36] did not find any rela-
tionship between homocysteine and hypertension in
patients with stroke. Furthermore, hypertensive stroke
survivors had an even lower homocysteine level than
those without hypertension.
Also methylenetetrahydrofolate reductase gene pol-
ymorphism and its homozygous Val/Val genotype,
which may result in an elevated homocysteine level,
does not seem to be a risk factor for hypertension. The
study of Nakata [37] on a Japanese population gave
amazing results. The frequency of Val/Val genotype
was significantly lower in hypertensive patients than
in controls. Subjects with the Ala allele had an al-
most twofold increased risk for hypertension, sug-
gesting that Val allele may be associated with lower
blood pressure.
In contrast, Wilken et al. [38] observed weak cor-
relation between Val allele and hypertension in male
patients. Val/val homozygotes were more prevalent
in patients with hypertension (13,3%) than in those
without (9,8%). The Val allele frequency was also
significantly higher among hypertensive patients
than normotensive ones. Wilken in a log-linear anal-
ysis observed a significant three-way interaction
among sex, hypertension and MTHFR genotypes.
The association between MTHFR and hypertension
was especially significant in male patients.
In conclusion, the results of published studies are
still not definitive. Our study suggests that an elevat-
ed homocysteine level may cause hypertension but
large cohort prospective studies are needed to ex-
plain whether an elevated homocysteine level is
a risk factor or may be a result of hypertension.
Summary
Background The aim of the study was to assess the
significance of association between hypertension
(Ht) and circulating homocysteine concentrations.
Material and methods 88 consecutive hypertensive
patients (62 men and 26 women, aged 18 to 72 years)
and 120 healthy controls (87 men and 33 women,
aged 32–81 years) were investigated. Homocysteine
was assayed using Fluorescence Polarisation Immu-
noassay on the IMx Analyser made by Axis
Biochemicals. Plasma folate and plasma vitamin
B12 were assayed with chemiluminescency and
IMMULITE Automated Analyser made by the
Diagnostic Products Corporation.
Results Homocysteine concentrations were higher
in patients than in controls (12,07 ± 5,1 vs. 10,72 ±
± 2,13 mmol/L, p < 0,001, adjusted for age). Elevated
homocysteine level -defined as a level above the 90th
percentile of the control distribution (≥ 13,52 mmol/L)
— was seen in 24% of the patients compared with 10%
of the control group (p < 0,05).
The odds ratio (OR) for Ht in persons with an el-
evated homocysteine level was 2,8 (95% CI 1,3–6,1,
p < 0,01). After adjustment for conventional risk
factors (age, gender, body mass index, smoking, fam-
ily history of cardiovascular disease, hyperlipidemia),
an elevated homocysteine level remained an inde-
pendent risk factor for Ht (OR 6,6, 95% CI 2,3–19,1,
Jacek Kądziela et al. Elevated Plasma Homocysteine Level as a Risk Factor for Hypertension
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